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Neria F, Caramelo C, Peinado H, Gonza´lez-Pacheco FR,
Deudero JJ, de Solis AJ, Ferna´ndez-Sa´nchez R, Pen˜ate S, Cano
A, and A´ngeles Castilla M. Mechanisms of endothelial cell
protection by blockade of the JAK2 pathway. Am J Physiol Cell
Physiol 292: C1123–C1131, 2007. First published October 11,
2006; doi:10.1152/ajpcell.00548.2005.—Inhibition of the JAK2/
STAT pathway has been implicated recently in cytoprotective mech-
anisms in both vascular smooth muscle cells and astrocytes. The
advent of JAK2-specific inhibitors provides a practical tool for the
study of this pathway in different cellular types. An interest in finding
methods to improve endothelial cell (EC) resistance to injury led us to
examine the effect of JAK2/STAT inhibition on EC protection.
Furthermore, the signaling pathways involved in JAK2/STAT inhibi-
tion-related actions were examined. Our results reveal, for the first
time, that blockade of JAK2 with the tyrosine kinase inhibitor AG490
strongly protects cultured EC against cell detachment-dependent
death and serum deprivation and increases reseeding efficiency. Con-
firmation of the specificity of the effects of JAK2 inhibition was
attained by finding protective effects on transfection with a dominant
negative JAK2. Furthermore, AG490 blocked serum deprivation-
induced phosphorylation of JAK2. In terms of mechanism, treatment
with AG490 induces several relevant responses, both in monolayer
and detached cells. These mechanisms include the following: 1)
Increase and nuclear translocation of the active, dephosphorylated
form of -catenin. In functional terms, this translocation is transcrip-
tionally active, and its protective effect is further supported by the
stimulation of EC cytoprotection by transfectionally induced excess of
-catenin. 2) Increase of platelet endothelial cell adhesion molecule
(PECAM)/CD31 levels. 3) Increase in total and phosphorylated AKT.
4) Increase in phosphorylated glycogen synthase kinase (GSK)3/.
The present findings imply potential practical applications of JAK2
inhibition on EC. These applications affect not only EC in the
monolayer but also circulating detached cells and involve mechanistic
interactions not previously described.
JAK2/STAT; cytoprotection; anoikis; AG490
INDUCTION OF ENDOTHELIAL CELL (EC) resistance to injury is a
critical issue in designing tools for vascular therapeutics. En-
dothelial preservation is important in an extremely ample array
of conditions, extending from pathologies in which endothelial
injury is the leading mechanism, e.g., malignant hypertension
or hemolytic-uremic syndrome (HUS), to arterial hypertension
or simply to mechanical endothelial damage as occurs during
vascular interventional procedures. Remarkably, a new per-
spective of interest has been opened with the recognition of the
role of endothelial precursors in the repair of the endothelial
layer (28).
Numerous studies have dealt with the subject of endothelial
protection, basically employing growth factors and stimulating
cytoprotective pathways, e.g., phosphatidylinositol 3-kinase
(PI3K)/AKT, stress proteins, or MAP kinases (19). The Janus
kinase/signal transducers and activators of the transcription
(JAK/STAT) pathway transmits information received from
extracellular peptide signals through transmembrane receptors
directly to target gene promoters in the nucleus, therefore
providing a mechanism for transcriptional regulation without
identified second messengers. While signaling through the
canonical JAK/STAT pathway has been extensively character-
ized in stimulated immune cells, emerging evidence indicates
that STATs also mediate responses to forms of cellular stress
as diverse as ischemia/reperfusion, endotoxin, ultraviolet light,
or hyperosmolarity (9). Notwithstanding, data are less than
homogeneous as to how JAK inhibition affects cell damage in
different models of ischemic injury (10, 15, 20). At present,
most of the information available on this subject comes from
the field of cardiovascular medicine. In this regard, JAK/STAT
signaling appears to have an important role in the development
of the cardioprotected phenotype associated with ischemic
preconditioning (15). On the other hand, double-edged effects
have been reported in models of myocardial infarction, i.e.,
while JAK/STAT activation reduces apoptosis in the myocar-
dial infarction border zone, JAK2/STAT inhibition by AG490
improves the increase of protein phosphatase-1 activity and
decreases the levels of p16-phospholamban, which underlie
myocardial dysfunction (10). Moreover, the inhibition of the
JAK/STAT pathway may result in a significant reduction in the
size of devitalized tissue and in the number of cardiomyocytes
undergoing apoptosis (20). Furthermore, JAK2/STAT is in-
volved in the anti-apoptotic effect of granulocyte colony-
stimulating factor in severely ischemic myocardium and endo-
thelium (13). Collectively, these data indicate that cellular
stress activates STATs in ways that can be either detrimental or
supportive of cell survival. Recently, a substantial, specific
piece of information has been added, by demonstrating that
JAK2 tyrosine kinase mediates oxidative stress-induced apop-
tosis in vascular smooth muscle cells (27) and astrocytes (11).
As a consequence, JAK2 inhibition induces cytoprotection
against oxidative aggression. In the same line of evidence,
oxidized low-density lipoproteins have been recently shown to
induce, by means of lipid peroxidation products, tyrosine
* F. Neria and C. Caramelo contributed equally to this study.
Address for reprint requests and other correspondence: Mª A´ngeles Castilla,
Laboratorio de Nefrologı´a-Hipertensio´n, Fundacio´n Jime´nez Dı´az, Univer-
sidad Auto´noma, Avda. Reyes Cato´licos 2, 28040 Madrid, Spain.
The costs of publication of this article were defrayed in part by the payment
of page charges. The article must therefore be hereby marked “advertisement”
in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Am J Physiol Cell Physiol 292: C1123–C1131, 2007.
First published October 11, 2006; doi:10.1152/ajpcell.00548.2005.
0363-6143/07 $8.00 Copyright © 2007 the American Physiological Societyhttp://www.ajpcell.org C1123
phosphorylation and activation of JAK2, STAT1, and STAT3,
therefore providing support to consider JAK2 as an oxidative
stress-activated kinase (21). The actual mechanisms involved
in these effects have not been sufficiently characterized; fur-
thermore, data on models with possible applications to vascular
pathology need to be generated.
To the best of our knowledge, no information has been
published regarding the putative role of the JAK2/STAT path-
way in cytoprotective or cytotoxic mechanisms on EC. In this
sense, two particularly important types of damage are growth
factor deprivation and cell detachment-related death. The latter
is mainly due to detachment-dependent apoptosis, a phenom-
enon that has been designated as anoikis. Anoikis is crucial in
determining the death of adult EC losing adherence to the
monolayer (12), and its inhibition can be attained in only a few
conditions. In this regard, previous literature (18) and prelim-
inary results from our laboratory (Castilla MA, unpublished
observations) have shown that inhibition of the glycogen syn-
thase kinase (GSK)3 pathway increases the survival of EC
against detachment-related cell death. In terms of mechanism,
inhibition of GSK3 with LiCl increases -catenin and favors
its nuclear translocation. In these circumstances, -catenin acts
as a survival factor against detachment-related cell death (26,
29). Also, it is known that GSK3 is a regulator of EC
proliferation and anoikis (18).
As a part of the interest of our laboratory on the study of
endothelial protective mechanisms (4–6), the hypothesis was
raised that JAK2/STAT inhibition may have relevant protec-
tive effects on cells permanently exposed to stress, of which
EC are a paradigm. Preliminary evidence from our laboratory
has shown that JAK2/STAT inhibition strongly protects EC
against oxidative damage (24). However, no data are available
to date on the effects of JAK2/STAT inhibition on other types
of injury involving EC. The advent of highly specific JAK2/
STAT inhibitors provides a useful tool for examining this
pathway (1, 11, 30).
The present study was aimed to analyze the hypothesis that
specific JAK2/STAT inhibition induces significant changes in
EC viability and to identify the mechanisms involved. Specific
attention was dedicated to the study of protection of EC against
detachment-related death, i.e., anoikis. A set of mutually re-
lated mechanisms with known endothelial protective proper-
ties, namely, -catenin levels and active -catenin transloca-
tion, platelet endothelial cell adhesion molecule-1 (PECAM-1)
expression, AKT phosphorylation, and potential apoptotic ac-
tivators and inhibitors were examined.
MATERIALS AND METHODS
EC Culture
Bovine aorta EC (BAEC) and human umbilical vein EC (HUVEC)
were obtained, characterized, and cultured as described (3, 4), in
accordance with the Guiding Principles for Research Involving Ani-
mals and Human Beings of the American Physiological Society (6).
BAEC were used as the primary experimental source, and HUVEC
were employed for complementary confirmatory experiments.
EC Challenge
The use of confluent, monolayer, or detached conditions was a
critical point of this investigation. Confluent EC were submitted to
either serum deprivation or cell detachment and suspension culture. In
all cases, vehicle alone (DMSO 0.1%), AG490 (Calbiochem, Bar-
celona, Spain), a tyrosine kinase-blocking inhibitor of JAK2 (11, 22,
27) or its control, and the structurally related non-JAK/STAT inhibitor
AG82 (Calbiochem, Barcelona, Spain) were added 45 min before the
experimental maneuvers were performed. The Src family protein
kinase inhibitor PP2 (10 mol/l, Calbiochem) was also used. Cell
viability was assessed by lactate dehydrogenase release (LDH), as
described (6). DNA fragmentation (DNA ladder) of EC in agarose
gels was used for further characterization of the apoptotic changes, as
described (16). Conventional hematoxylin and eosin staining was used
to obtain cell images under the different treatments.
Detached Cell Survival and Reseeding Assays
For triggering detachment-related cell death, after pretreatment,
BAEC were removed from the culture plates with trypsin-EDTA and
resuspended in 1% FBS medium. This small amount of FBS was
necessary to avoid additional damage due to serum starvation. Resus-
pended cells were seeded onto tissue culture plates coated with
poly-2-hydroxyethyl methacrylate (Poly-HEMA) (Sigma-Aldrich,
Madrid, Spain). An additional system was used as a comparative
control in selected experiments, i.e., BAEC were seeded into a spinner
flask (Integra Biosciences, Chur, Switzerland) coated with Sigmacote
(Sigma-Aldrich). At the times indicated, BAEC were harvested and
processed by flow cytometry, as described (6). Both treatments
prevented cell adhesion and hence induced anoikis.
For reseeding assay, BAEC cultured in suspension were allowed to
grow for 24 h onto Matrigel-coated plates (Matrigel; BD Transduction
Laboratories, Madrid, Spain) as described (6). BAEC were fixed,
stained with crystal violet, and microphotographed. Cells were
counted on 10 randomly chosen high-power fields by two independent
observers blinded for the type of specific experiment.
Studies on -Catenin and PECAM-1
-Catenin and PECAM-1 (also known as CD31) levels were
assessed by Western blot on total and/or nuclear proteins, using
specific antibodies (-catenin, BD Transduction Laboratories;
PECAM-1, R&D Systems, Minneapolis, MN). -Tubulin was used as
loading control as described (6).
Further assessment of -catenin and PECAM-1 was performed by
confocal immunofluorescence. For this purpose, cells grown on glass
coverslips were fixed with Merckofix (Merck, Barcelona, Spain),
permeabilized (0.2% Triton X-100, 15 min), and incubated in PBS
with 1% bovine serum albumin. Slides were incubated overnight with
the primary antibodies, washed (PBS, 5 min, 3), and incubated with
a specific secondary antibody coupled to FITC (Sigma-Aldrich). For
visualization of nuclei, cells were incubated for 45 min with pro-
pidium iodide. Confocal images were obtained with a Confocal
System TCS SP20 (Leica, Madrid, Spain). Image quantitation was
done by means of the program Image J (National Institutes of Health,
Bethesda, MD). Ten randomly selected high-power fields were used
for each quantitation.
A -catenin/TCF activity reporter assay was performed to assess
-catenin functionality. For transfections, cells grown to 60–80%
confluence were transfected with 20 ng of pTK-Renilla (Promega,
Madrid, Spain) and 200 ng of either pTOPFLASH (Top) or pFOP-
FLASH (Fop) containing multimerized wild-type and mutated Lef1/
Tcf binding sites, respectively, fused to a luciferase reporter gene (a
gift of H. Clevers; University Hospital, Utrecht, The Netherlands).
Transfections (4-set duplicates, 6 h) were performed with lipo-
fectamine (Gibco, Madrid, Spain). BAEC were treated in the pres-
ence/absence of AG490 for 24 h, and afterward, luciferase and Renilla
activities were measured using the Dual Luciferase Reporter Kit
(Promega). When needed, 400 ng of activator plasmid encoding a
metabolically stabilized -catenin S33Y (a gift of A. Ben Ze’ev;
Weizmann Institute, Rehovot, Israel) were added as indicated. DNA
quantities were normalized with empty pCI-neovector. To analyze
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whether the increased -catenin was active, additional experiments
were performed employing a specific antibody against the active form
of -catenin, dephosphorylated on Ser47 or Thr41 (Upstate, Lake
Placid, NY).
Transient Transfections
Different plasmids were transfected in BAEC using a CaCl2-based
method. Briefly, BAEC were grown near confluence (80–90%). The
optimal transfection was achieved at a CaCl2-to-DNA ratio of 6
mmol/l to 10 g/ml, respectively; the CaCl2-DNA complex was
performed in HBS buffer [21 mmol/l HEPES, 0.14 mol/l NaCl, 5.5
mmol/l D()-glucose, 50 mmol/l KCl, 1.32 mol/l Na2HPO4 at pH
7.1]. The transfection mix remained for an additional 6 h; then, BAEC
were washed with PBS (2), and growth medium was added until
confluence was reached (48 h). Cell challenge was performed as
described above. To evaluate transfection efficiency, all assays were
also transfected using pEGFP-N1 vector (BD). Transfection efficiency
was 50% in all cases.
A wildtype form of JAK2 (pBOS-HAJAK2) and a kinase domain
mutant of JAK2 (pBOS-HAdkJAK2) (a gift from Dr. Dwayne L.
Barber, Ontario Cancer Institute, Toronto, Canada) were used. For
-catenin transfection, a wildtype form of -catenin in a pCINeo
vector was used (a gift of A. Ben Ze’ev; Weizmann Institute, Rehovot,
Israel). In all cases, an empty vector was employed as control.
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay (EMSA) was employed to
further ascertain the specificity of the effects of AG490. EMSA was
performed using nuclear proteins (8 g) and different consensus
oligonucleotides (dsDNA, 0.5 ng) labeled with [-32P]dATP in bind-
ing buffer 1. Poly(dI-dC) was included as a competitive DNA. After
incubation, samples were separated by acrylamide-bisacrylamide gels.
Dried gels were exposed to X-Omat films. Commercial oligonucleo-
tides of STAT3 and TFII were used (Santa Cruz Biotechnology, Santa
Cruz, CA). Vascular endothelial growth factor (VEGF, R&D Sys-
tems) was used as a positive control of STAT3 nuclear binding (31).
Analysis of Protective and Apoptotic Pathways
BAEC protective pathways were analyzed by Western blot, using
rabbit polyclonal anti-Bax (Santa Cruz Biotechnology), mouse mono-
clonal anti-Bcl2 (BD Transduction Laboratories), rabbit polyclonal
anti-phospho-AKT (Ser473) and phospho-GSK3/ (Ser21/9) and their
respective loading controls, anti-AKT and anti-GSK3 (Cell Signal-
ing Technology, Beverly, MA). Specific antibodies against JAK2 and
phospho-JAK2 and against STAT1, STAT3, STAT5, and STAT6 and
their respective phosphorylated forms and loading controls were also
used (Cell Signaling Technology). Caspase-3 activity was assayed on
confluent BAEC with caspase-3 fluorogenic substrate Ac-DEVD-
AMC (BD Transduction Laboratories). Activity was expressed as the
signal in a luminometer (exciting wavelength 380 nm, and emission
wavelength 440 nm).
Statistics
Results are expressed as means 	 SE. Unless stated otherwise,
each value corresponds to a minimum of five triplicate experiments.
Comparisons were done by ANOVA or paired or unpaired Student’s
t-test, when appropriate. Fisher and Scheffe´’s tests for multiple com-
parisons were used to determine the P value, which was considered
significant at 0.05. The statistical analyses were performed with the
Windows SPSS 10.0 package (SPSS, Chicago, IL).
RESULTS
For facilitating their visualization, results have been grouped
in experiments involving either attached or detached EC.
Experiments on Monolayer, Attached EC
Endothelial cytoprotection by JAK/STAT inhibition. Treat-
ment with the specific JAK2 inhibitor AG490 protected con-
fluent monolayer BAEC against serum deprivation (Fig. 1).
This effect was significant from the 10 mol/l concentration. A
similar effect was obtained by incubating confluent HUVEC
with AG490 (50 mol/l) (%relative cell death with respect to
100% control: 69.5 	 5.7%, P  0.02). The 50 mol/l
concentration was henceforth used for examining specific
points.
A first, fundamental issue was to assess the specificity of the
effect of AG490 on the JAK/STAT pathway in BAEC. Such
specificity was supported by the results of several experiments:
Fig. 1. Cytoprotective effect of AG490 on
monolayer endothelial cells (EC). EC damage
as induced by FBS depletion on confluent
monolayer bovine aorta endothelial cells
(BAEC) treated with fresh medium (FM) and
FM  AG490 at different concentrations.
Cell damage was assessed by lactate dehy-
drogenase (LDH) release at 48 h (top: *P 
0.05 and **P  0.01 with respect to the
baseline, n 
 6 triplicate experiments). FM
alone was considered as 100% cell death.
Phenotypic characteristics of BAEC pro-
cessed in the same experimental conditions as
above are shown at bottom (hematoxylin and
eosin, 400). All wells were seeded with the
same amount of cells. As can be seen, the
integrity of the cell layer increases directly
with AG490.
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1) the inhibition of serum deprivation-induced JAK2 phosphor-
ylation by AG490 (Fig. 2A); 2) the abolition of VEGF-induced
STAT3 DNA binding (EMSA) (data not shown); 3) the inhi-
bition of STAT3 and STAT6 phosphorylation by AG490 (Fig.
2B); and 4) the absence of EC protection by the structurally
similar compound AG82, which is devoid of JAK2 inhibitory
activity [relative cell death with respect to 100% in control
cells: 97.5 	 2.1%, P 
 not significant (NS) with respect to
control cells]. These results were completed by experiments
done in detached conditions (see below).
Changes in -catenin and PECAM-1. On the basis of pre-
vious evidence (2, 29), the hypothesis was raised that treatment
with AG490 could act on the levels and distribution of -cate-
nin. As shown in Fig. 3A, AG490 induced a marked increase in
total and nuclear -catenin. The increase of nuclear -catenin
persisted in BAEC pretreated with AG490 and lately cultured
in suspension (see below). Additional experiments were done
to more specifically assess whether the -catenin accumulated
in the nuclear extract corresponded to the active form. By
means of an specific antibody, we found that treatment with
AG490 induces nuclear accumulation of the active, dephos-
phorylated form of -catenin (Fig. 3A, lane 3, left). When the
-catenin signal was further examined by confocal micros-
copy, treatment with media 20% FBS induced a marked
increase of -catenin, either at the intercellular junctions,
cytosol, or nucleus (Fig. 4A). Treatment with AG490 induced
changes in -catenin with a pattern similar to that of 20% FBS,
including redistribution to the nucleus. BAEC treated with
fresh medium (FM) alone had markedly less amounts of
-catenin, which was located only at the intercellular junctions
(Fig. 4A, detail). By comparison, the GSK3 inhibitor LiCl
favored the localization of -catenin to the nucleus as well as
an increase of lesser magnitude in both cell junctions and
cytoplasm (Fig. 4A).
At this point, the relevant question was to know whether the
increase in nuclear -catenin under the effect of AG490 was
functional. As shown in Fig. 3B, AG490 induced a significant
increase (1.95 	 0.2 times, P  0.01) of TOP/FOP activity,
comparable with the levels obtained after -catenin transient
transfection (2.28 	 0.2 times, P  0.01). Additionally, the
combination of -catenin transfection with AG490 treatment
Fig. 2. AG490 effects on JAK2/STAT pathway. A: Western blot analysis of
phosphorylated JAK2 from total lysates of confluent, monolayer EC, treated
with FM or AG490 (50 mol/l) for times indicated. Total JAK2 was used as
loading control. B: Western blot analysis of the phosphorylation state of
different STAT proteins. Lysates were obtained from confluent monolayer EC
treated with FM 20% FBS, FM alone, or FM AG490 (50 mol/l) for 24 h.
Respective total STAT antibodies were used as loading control.
Fig. 3. Changes in total and nuclear -catenin and -catenin transcriptional
activity under the influence of AG490. A: Western blot of nuclear and total
-catenin extracted from BAEC pretreated with FM  20% FBS, FM alone,
or FM  AG490 (50 mol/l) for 24 h. To further identify the activation of
-catenin, an antibody against active -catenin, i.e., dephosphorylated on Ser37
or Thr41, was also employed, and the intensity of the bands was quantified with
respect to -tubulin and displayed. -Tubulin was used as loading control. B:
-catenin/Tcf activity assay using TOP/FOP luciferase reporter in EC treated
with FM or FM  AG490 (50 mol/l). Bars denoted as -cat indicate
cotransfection with a plasmid with the -catenin sequence for overexpression
(*P  0.05 with respect to equal condition of FM; **P  0.01 with respect to
the first bar, and P  0.05 with respect to second and third bars). -P,
dephosphorylated.
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promoted a synergistic activation of TOP/FOP activity. Col-
lectively, all these data indicate a functional role for the
translocation of -catenin observed in this system after AG490
treatment.
A marked increase in PECAM-1 was observed under the
same conditions of the -catenin changes (Fig. 4B). This
increase was further confirmed by Western blot (data not
shown).
Additional Western blot studies were performed to further
characterize the effects of JAK2 inhibition by AG490.
These studies suggest that, at least in baseline conditions,
AG490 may improve BAEC resistance by means of AKT
rather than by other anti-apoptotic proteins, as follows. 1) A
significant increase in AKT protein was observed (4.5 	
0.3-fold increase in AG490 with respect to FM, P  0.05).
2) No significant changes were found in the Bcl2/Bax ratio
(FM 1.00 	 0.18 vs. AG490 1.19 	 0.21, P 
 0.07, n 
 5).
In the same regard, no changes by AG490 were detected on
caspase-3 activity (FM 100 	 8.1 vs. AG490 113.91 	 17.3
arbitrary units, P 
 NS).
Experiments in Detached Conditions
Because EC survival is critically dependent on cell-matrix
and cell-cell adhesion (23), a set of experiments was performed
to assess the role of JAK2 pathway inhibition in cell death
related to disrupted adhesion and culture in suspension.
A clear-cut protective effect of JAK2 inhibition was evident
on BAEC cultured in suspension. BAEC were pretreated with
FM containing no FBS or 20% FBS or FM  AG490 at 50
mol/l. As shown in Fig. 5A, pretreatment with AG490 in-
duced a marked increment in BAEC viability at different times
after detachment. Furthermore, inhibition of apoptotic death in
detached cells was assessed by examining DNA degradation.
As shown in Fig. 5B, treatment with AG490 blocked DNA
laddering, thus indicating that inhibition of apoptosis was an
important component of AG490-induced protection against the
effects of detachment.
The specific role of JAK2 inhibition was further ascer-
tained by assessing cell death in BAEC transfected with a
mutant dominant negative of the JAK2 kinase domain (a gift
of Dr Dwayne L. Barber, Ontario Cancer Institute, Toronto,
Canada). As seen in Fig. 5C, cell death was significantly
inhibited in BAEC transfected with deficient kinase JAK2
against wildtype JAK2 or empty vector. This can be con-
sidered a gold standard of JAK2 inhibition and supports the
attribution of AG490 effects to JAK2 blockade. From here
on, and because of the more direct feasibility of the exper-
iments, the studies on mechanisms have been done mostly
Fig. 4. A: immunofluorescence of -catenin, as
visualized by confocal microscopy. Confluent EC
grown on glass coverslips were treated with FM,
FM  20% FBS, FM  AG490 (50 mol/l), or
FM LiCl (20 mmol/l) (positive control) for 24 h.
Images show whole cell -catenin localization
with differentiated nuclear contrast (400). De-
tailed images of cells treated with either FM or
AG490 are shown without using nuclear contrast,
for illustrating nuclear translocation of -catenin.
Nuclear staining has been omitted, to improve
visualization of the -catenin B: immunofluores-
cence of platelet endothelial cell adhesion mole-
cule-1 (PECAM-1). The same treatments as in A
were employed, except for LiCl.
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using AG490 rather than JAK2 kinase domain dominant
negative transfection.
Because of the putative effects of AG490 on the Src path-
way, further experiments were done to analyze the possible
participation of Src in the observed protective actions against
detachment-related cell death. These experiments showed no
effect of the Src inhibitor PP2 on the survival of detached
BAEC, as follows: %cell death after 8 h of suspension culture,
FM 32.9 	 5.7 vs. PP2 35.1 	 6.2 (n 
 4, P 
 NS).
The effect of AG490 was not only relevant to BAEC
damage, as assessed by flow cytometry, but was also function-
ally significant in terms of the BAEC growth capability in
reseeding (Fig. 6). Pretreatment with AG490 (50 mol/l)
induced a marked increase in the yield of reseeding on Matrigel
after culture in suspension (no. of cells 7.8 	 1.2, 9.4 	 0.8,
and 12.3 	 1.1 times higher in AG490-treated samples after 8,
24, and 48 h, respectively; all P  0.001 with respect to
vehicle-treated controls, n 
 5, triplicate experiments).
With regard to the mechanisms involved in the increased
survival in suspension after JAK2/STAT inhibition, the find-
ings in detached BAEC were in agreement with the results
obtained in monolayer BAEC. As shown in Fig. 7A (top),
nuclear -catenin levels are increased in BAEC pretreated with
AG490 and lately cultured in suspension compared with FM or
20% FBS. This result posed the question of whether the
increased -catenin has a significant role in improving BAEC
survival in detached conditions. This issue was examined by
transfecting BAEC with a plasmid that increases the expression
of -catenin. In these conditions, a marked increase in de-
tached BAEC survival was observed. (Fig. 7B), thereby sup-
porting the importance of -catenin as a major mechanism.
Additional experiments were done to further ascertain the
putative mechanisms of the AG490 protective effects in non-
adherent cells. As can also be seen in Fig. 7A, meaningful
effects of AG490 treatment were found on the following
potentially protective mechanisms: 1) higher levels of total
AKT; 2) increased levels of phosphorylated AKT, i.e., acti-
vated AKT; and 3) increased levels of phosphorylated GSK3,
i.e., inactivated GSK3.
DISCUSSION
Our results provide the first evidence of the potent endothe-
lial cytoprotective effect induced by specific inhibition of the
JAK2/STAT pathway. Actually, a singularly important lethal
process, i.e., detachment-related cell death, is significantly
blocked by pretreatment with the specific JAK2 inhibitor, the
tyrphostin AG490, and specifically confirmed by transfection
of a JAK2 dominant negative. This effect is accompanied by an
increase and redistribution of -catenin, and by higher levels of
total and active phosphorylated forms of a key defensive
protein, AKT. Furthermore, the present experiments reveal that
a series of mechanisms are activated on JAK2/STAT inhibi-
tion.
Although the mechanistic distinction between apoptotic and
necrotic forms of cell death is not a central issue of the present
investigation, our results, using both DNA laddering and LDH
release, indicate that AG490 exerts protective effects on both
types of EC elimination. In this regard, the relevant point is that
JAK2/STAT inhibition protects BAEC against death triggered
by either serum deprivation or detachment.
In BAEC, -catenin acts both as a vascular endothelial
(VE)-cadherin-associated protein in the adherens junction
complex and also as a transcriptional activator; the latter role is
mediated through its interaction with members of the TCF/Lef
family of transcription factors in Wnt signaling (14, 26, 29). In
adherent nonstimulated cells, -catenin is localized to the
adhesion complexes; simultaneously, its cytoplasmic levels are
kept low, by association with other proteins, e.g., adenomatous
poliposis coli (APC) or GSK3, which drive cytoplasmic
-catenin to proteasome-mediated degradation. The mecha-
nisms identified in the present study are time related to the
protective effect of JAK2 inhibition by AG490. Changes in
Fig. 5. Protective effect of JAK2 inhibition on EC detachment-induced cell
death/anoikis. A: cell death progression in EC cultured in suspension after
pretreatment (24 h) with FM, FM with 20% FBS, or FM AG490 (50 mol/l)
as assayed by flow cytometry (*P  0.01 with respect to the 20% FBS and
AG490 curves and **P 0.02 with respect to the 8-h point of 20% FBS curve,
n 
 5 triplicate experiments). The curves correspond to 5 experiments run in
parallel. In all the samples, the same concentration of vehicle (DMSO, 0.1%)
was used. Time 0h corresponds to the moment of cell detachment. B: DNA
ladder from EC, treated as described in Fig. 4A. DNA was extracted at
indicated times in suspension culture and run in low-melting agarose gel. C:
cell death analysis measured at 8 h of suspension culture in EC transfected with
plasmids encoding a wildtype form of JAK2 (JAK2 WT), a kinase-deficient
form of JAK2 (JAK2 DK), or the empty vector (*P  0.01 with respect to the
other conditions).
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Fig. 6. Effect of AG490 on reseeding efficacy of EC after different times of culture in suspension. EC were pretreated with FM, FM  20% FBS, or FM 
AG490 (50 mol/l) for 24 h and cultured in suspension for the times indicated, as described in MATERIALS AND METHODS. Thereafter, EC were collected and
reseeded on 12-well plates coated with Matrigel. EC were allowed to grow for 24 h, fixed, stained with crystal violet, and microphotographed (100).
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quantity and distribution of -catenin, but especially the dem-
onstration of the nuclear localization of its active dephospho-
rylated form, and the presence of -catenin-dependent tran-
scriptional activity support a significant role of this protein in
the BAEC protective effects; in fact, the pattern found is
coincident with that described in death-resistant hemangio-
ma-derived cell lines (17).
Our results involving PECAM-1 are of importance concern-
ing the -catenin increase and redistribution to the nucleus.
Accordingly, as found by Biswas et al. (2), PECAM-1 is
determinately associated with protection from degradation and
with increased nuclear -catenin. In consequence, the simul-
taneous increase of PECAM-1 and -catenin accompanying
JAK2 inhibition is compatible with the existence of an opera-
tional sequence of BAEC protection. Of specific interest, our
data go beyond the existing information, all in adherent BAEC,
and provide a first piece of evidence on the relationship of
-catenin with the fate of BAEC in suspension. The present
results strongly suggest that activation and nuclear transloca-
tion of -catenin can be key elements of survival after detach-
ment.
In resting cells, GSK3 is highly active, and in growth factor
deprivation conditions, GSK3 activation is able to increase
EC apoptosis (18). Conversely, inhibition of GSK3 signaling,
mainly through phosphorylation, protects cells from apoptosis
under conditions of mitogen deprivation and regulates cell
death by anoikis (18). Inhibition of GSK3 activity results in
blockade of -catenin phosphorylation and subsequent stabili-
zation of cytoplasmic -catenin, which eventually translocates
to the nucleus (8). Our results showing increased levels of
phosphorylated GSK3 in BAEC maintained in suspension
after pretreatment with AG490 are inversely related to the
increase in -catenin observed in the same circumstances.
Since results showing protective effects of GSK3 inhibi-
tion have been previously published (18), we focused our
studies only on the comparison of -catenin patterns of re-
sponse to LiCl and AG490. In this setting, relevant similarities
concerning -catenin turnover were detected. In fact, the in-
creased phosphorylation of GSK3 and -catenin increase and
translocation under the effect of AG490 are hereby newly
described.
Of specific interest, pretreatment of BAEC with AG490
induced a major increase in survival of detached BAEC. This
effect was even stronger than that obtained by means of growth
factor-rich media, i.e., 20% FBS, and had significant conse-
quences on BAEC reseeding. In fact, no reliable pharmacolog-
ical tools are available to both prolong life of detached BAEC
and enhance their reseeding efficacy, as done by means of
AG490. This result can have several practical applications in
the field of EC protection.
In terms of mechanism, a strong support for the protective
role of -catenin in the present conditions was provided by the
results obtained in -catenin-transfected BAEC; these cells had
a markedly higher survival capability than their empty vector
counterparts. To the best of our knowledge, this is the first
demonstration that increased -catenin has a relevant role in
prolonging life of BAEC detached from the endothelial mono-
layer. Furthermore, our results indicate that at least one well-
known protective pathway, i.e., PI3K/AKT, is persistently
activated in detached conditions under the influence of AG490.
The actual functionality of this activation needs further study,
by analyzing specific targets of PI3K/AKT activation. On the
contrary, the data obtained in the presence of the Src inhibitor,
PP2, suggest the absence of a relevant involvement of the Src
pathway in BAEC death after detachment and therefore make
improbable any possible role of Src inhibition in the effects of
AG490. Moreover, it should be noted that the Src inhibitory
capability of AG490, albeit in a different experimental system,
appears to be rather weak (25).
The present results provide a set of new findings, with
relevant potential in terms of practical applications. The
strength of the protective effect of JAK2 inhibition against
diverse injuries, and particularly against cell detachment-in-
duced death, is particularly valuable.
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